New Dual Vaccine for Lassa Fever and Rabies Shows Early Promise in Human Trials

An initial clinical trial has yielded encouraging outcomes for a novel vaccine targeting both Lassa fever and rabies. The study indicated that the vaccine is safe and effectively stimulates immune responses against both viruses. This development is significant as Lassa fever is a major public health concern, particularly in West Africa, with no existing approved vaccines.